
CO41012 | IPATunity150
NCT04060862
JCP080
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)
Status:
Opening Soon

II/III
Phase

2nd
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
ER+, HER2-
Investigational
Product
Ipatasertib
AKT inhibitor (p.o.)
Treatment Arms
o Experimental: Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant
o Placebo Comparator: Phase 3: Placebo + Palbociclib + Fulvestrant